Greg Davis

MedShape, Inc. develops and commercializes a portfolio of surgical solutions that use patented material technologies. It offers ExoShape soft tissue fasteners for fixation of the soft tissue graft on the tibial side of the knee joint in anterior cruciate ligament (ACL)reconstructions; and The ExoShape teno soft tissue fasteners for the fixation of connective soft tissues (tendons and ligaments) to bone during tenodesis, tendon transfer, and ligament reconstruction procedures in the extremities. The company was founded by Douglas J. Pacaccio and Kenneth A. Gall in 2005 and is headquartered in Atlanta, GA.

restor3d, Inc. provides health care services. The company was founded in 2017 and is headquartered in Durham, NC.

Deep Blue Medical Advances, Inc. operates as a biotechnology firm. It offers t-line mesh and anchor clips solutions. The company was founded by Howard Levinson and Ken Gall in March 2015 and is headquartered in Durham, NC.

Sparta Biomedical, Inc. has developed a breakthrough device called ORMI™ to treat knee osteoarthritis. The company is based in Madison, NJ. The device has been granted breakthrough device designation by the FDA. The company is committed to improving motion, reducing pain, and increasing the quality of life of patients with osteoarthritis. ORMI™ is different from other technologies that focus on cartilage regeneration approaches, which can take a long time to grow and not be as strong as the original. The company was founded by Dushyanth Surakanti and Dimitrios Angelis, and Dushyanth Surakanti has been the CEO since incorporation.

Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC.

VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.